SecBot SecBot
Biotech Drug Report Generated Oct 29, 2026

ENFLONSIA

MRK·Merck & Co., Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and launched in the U.S. (June 2025). The sBLA for second-season use in high-risk children under two has a PDUFA date of March 22, 2027.
Why 4/10
The next hard, dated catalyst is the FDA PDUFA decision on March 22, 2027 for the sBLA to expand ENFLONSIA's indication to children under two at increased risk during their second RSV season. However, the drug is already approved and commercializing, and its forecast peak sales (~$892M globally by 2031) are a small fraction of Merck's $65B+ annual revenue, so this label expansion is unlikely to drive a major share-price move.
Actionable Insight NEUTRAL

The next hard catalyst is the FDA PDUFA decision on the sBLA to expand ENFLONSIA's label to children under two at increased risk during their second RSV season, set for March 22, 2027. An approval would incrementally expand the addressable market but is unlikely to move Merck's shares materially given the drug's small revenue contribution relative to the company's $65B+ annual sales. The EMA review is running in parallel.

Price Chart

Loading chart...

Executive Summary

ENFLONSIA (clesrovimab-cfor) is Merck's FDA-approved preventive monoclonal antibody for RSV lower respiratory tract disease in infants, cleared in June 2025. It competes with Sanofi/AstraZeneca's Beyfortus but offers a convenience edge as the only weight-independent, single-dose option. The drug is already on the market for the 2025-2026 RSV season. A supplemental BLA to expand the label to high-risk children under two during their second RSV season was accepted by the FDA in August 2026, with a PDUFA decision date of March 22, 2027. While ENFLONSIA addresses a large pediatric market, its forecast peak sales of roughly $892M globally by 2031 are a small fraction of Merck's $65B+ annual revenue, making it a modest growth contributor rather than a transformative asset for the company.

How It Works

ENFLONSIA is a preventive monoclonal antibody, a lab-made protein that acts like the body's natural antibodies. It is given as a single shot before or during RSV season and binds to the RSV virus, neutralizing it and preventing it from infecting cells in the lungs. This provides passive immunity (the body does not need to make its own antibodies) that lasts for the entire RSV season. Unlike the main competitor Beyfortus, ENFLONSIA uses the same dose for all infants regardless of weight.

Trial Status

ENFLONSIA was approved by the FDA on June 9, 2025 based on the Phase 2b/3 CLEVER clinical program (Trials 004 and 007), which demonstrated an 84.3% reduction in RSV-related hospitalizations versus placebo through 5 months. The Phase 3 SMART trial evaluated a second-season 210 mg dose in high-risk children under two, supporting the sBLA filed in August 2026. The CDC's ACIP has reviewed and recommended the drug for routine infant immunization.

The Two-Sided Case

▲ Bull Case4
ENFLONSIA is the first and only RSV preventive option that uses a single, fixed dose regardless of infant weight, a meaningful convenience advantage over Beyfortus which requires weight-based dosing.
Pivotal trial data showed strong efficacy: an 84.3% reduction in RSV-related hospitalizations versus placebo through 5 months (CLEVER trial), and up to 76% reduction in RSV hospitalizations per published analyses.
The sBLA for second-season protection in high-risk children under two (PDUFA March 22, 2027) could expand the addressable market, and the EMA has accepted a parallel application for EU approval.
Multiple analysts raised price targets on MRK in August-October 2026 (Barclays to $180, Scotiabank to $180, Wolfe Research to $180, UBS to $175), reflecting broader pipeline optimism including ENFLONSIA's launch.
▼ Bear Case4
ENFLONSIA faces entrenched competition from Sanofi/AstraZeneca's Beyfortus (nirsevimab), which was approved in 2022 and already has first-mover advantage in the pediatric RSV prophylaxis market.
Forecast peak sales of roughly $892M globally by 2031 (per GlobalData) represent less than 1.5% of Merck's current annual revenue, making this drug a minor contributor to the overall investment thesis for MRK.
The sBLA label expansion to second-season children is not a binary event; the drug is already approved and commercializing, limiting any upside surprise.
Insider selling in August 2026 (EVP Chirfi sold $1.35M, EVP Zachary sold ~$10.7M, EVP DeLuca multiple sales) may signal limited near-term conviction at the executive level.

Upcoming Catalysts

  • FDA PDUFA decision on sBLA for second-season RSV prevention in high-risk children under two: March 22, 2027
  • EMA decision on parallel EU marketing authorization expansion (application accepted July 2026)
  • RSV season uptake data and commercial launch metrics through 2026-2027 season

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Merck & Co., Inc. 8-K MRK ·Originating report

Sources · 10

Hover a chip for the title
1 merck.com2 merck.com3 fda.gov4 novapharmanews.com5 globaldata.com6 drugtopics.com7 pmc.ncbi.nlm.nih.gov8 cdc.gov9 biopharminternational.com10 sec.gov